Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 13990.0
(-1.82%)
KRW 13990.0
(-1.82%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.04 Billion KRW | 101.51% |
| 2022 | 1.94 Billion KRW | 27.53% |
| 2021 | 1.52 Billion KRW | -56.49% |
| 2020 | 3.5 Billion KRW | -69.38% |
| 2019 | 11.45 Billion KRW | -16.48% |
| 2018 | 13.71 Billion KRW | -1.1% |
| 2017 | 13.86 Billion KRW | 19.98% |
| 2016 | 11.55 Billion KRW | 0.16% |
| 2015 | 11.54 Billion KRW | 38.14% |
| 2014 | 8.35 Billion KRW | 56.67% |
| 2013 | 5.33 Billion KRW | -39.85% |
| 2012 | 8.86 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.79 Billion KRW | 1223.58% |
| 2024 Q2 | -5.05 Million KRW | -97.17% |
| 2023 Q3 | 769.59 Million KRW | -48.58% |
| 2023 Q1 | 1.44 Billion KRW | 257.36% |
| 2023 FY | 3.92 Billion KRW | 101.51% |
| 2023 Q4 | 211.32 Million KRW | -72.54% |
| 2023 Q2 | 1.49 Billion KRW | 3.63% |
| 2022 FY | 1.94 Billion KRW | 27.53% |
| 2022 Q4 | 404.14 Million KRW | -50.61% |
| 2022 Q1 | 571.29 Million KRW | 168.79% |
| 2022 Q2 | -141.43 Million KRW | -124.76% |
| 2022 Q3 | 818.22 Million KRW | 678.51% |
| 2021 Q1 | 255.79 Million KRW | -19.09% |
| 2021 Q4 | 212.54 Million KRW | -73.79% |
| 2021 FY | 1.52 Billion KRW | -56.49% |
| 2021 Q2 | 285.38 Million KRW | 11.57% |
| 2021 Q3 | 810.81 Million KRW | 184.11% |
| 2020 Q1 | 2.54 Billion KRW | -31.99% |
| 2020 Q3 | 1.66 Billion KRW | -10.98% |
| 2020 Q4 | 316.15 Million KRW | -81.05% |
| 2020 FY | 3.5 Billion KRW | -69.38% |
| 2020 Q2 | 1.87 Billion KRW | -26.51% |
| 2019 Q4 | 3.74 Billion KRW | 20.4% |
| 2019 Q3 | 3.11 Billion KRW | -7.78% |
| 2019 Q2 | 3.37 Billion KRW | 2.54% |
| 2019 Q1 | 3.29 Billion KRW | 12.36% |
| 2019 FY | 11.45 Billion KRW | -16.48% |
| 2018 FY | 13.71 Billion KRW | -1.1% |
| 2018 Q3 | 3.36 Billion KRW | -15.72% |
| 2018 Q2 | 3.99 Billion KRW | 19.4% |
| 2018 Q1 | 3.34 Billion KRW | -21.44% |
| 2018 Q4 | 2.93 Billion KRW | -12.87% |
| 2017 Q3 | 4.06 Billion KRW | 20.01% |
| 2017 FY | 13.86 Billion KRW | 19.98% |
| 2017 Q2 | 3.38 Billion KRW | 13.47% |
| 2017 Q1 | 2.98 Billion KRW | 23.37% |
| 2017 Q4 | 4.25 Billion KRW | 4.77% |
| 2016 Q3 | 2.37 Billion KRW | -29.99% |
| 2016 Q4 | 2.41 Billion KRW | 1.65% |
| 2016 FY | 11.55 Billion KRW | 0.16% |
| 2016 Q1 | 3.62 Billion KRW | 35.35% |
| 2016 Q2 | 3.39 Billion KRW | -6.17% |
| 2015 Q3 | 3.53 Billion KRW | 26.45% |
| 2015 Q1 | 2.96 Billion KRW | 22.44% |
| 2015 FY | 11.54 Billion KRW | 38.14% |
| 2015 Q4 | 2.67 Billion KRW | -24.44% |
| 2015 Q2 | 2.79 Billion KRW | -5.68% |
| 2014 Q3 | 2.6 Billion KRW | 53.02% |
| 2014 Q1 | 1.62 Billion KRW | 63.13% |
| 2014 FY | 8.35 Billion KRW | 56.67% |
| 2014 Q4 | 2.42 Billion KRW | -6.95% |
| 2014 Q2 | 1.7 Billion KRW | 4.78% |
| 2013 Q2 | 871.95 Million KRW | -58.58% |
| 2013 Q4 | 995.86 Million KRW | -26.77% |
| 2013 Q3 | 1.35 Billion KRW | 55.95% |
| 2013 FY | 5.33 Billion KRW | -39.85% |
| 2013 Q1 | 2.1 Billion KRW | -49.88% |
| 2012 Q4 | 4.2 Billion KRW | 0.0% |
| 2012 FY | 8.86 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 94.48 Billion KRW | 94.665% |
| ST Pharm Co.,Ltd. | 106.62 Billion KRW | 95.272% |
| ABL Bio Inc. | 65.5 Billion KRW | 92.304% |
| Cellid, Co., Ltd. | -2.66 Billion KRW | 289.263% |